| Document |
Document Title |
|
WO/2010/151489A1 |
A chlorinating agent such as a chloroiminium species is used to remove or neutralize tertiary acetamide present as a contaminant in a tertiary formamide solvent. Tertiary formamide solvent purified or treated in this manner can be used a...
|
|
WO/2010/149760A2 |
The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) with amino acids or peptides and pharmaceutical compositions containing such prodrugs. Methods for providing pain relief, treating arrhythmia, dec...
|
|
WO/2010/145992A1 |
The present invention relates to benzoxazinones of the general formula (I) wherein the variables are defined according to the description, processes and intermediates for preparing the benzoxazinones of the formula (I), compositions comp...
|
|
WO/2010/143409A1 |
Disclosed are: a process for producing a salt of an optically active thiazolylalanine derivative which has a desired configuration by converting a thiazolylalanine derivative into a salt thereof and crystallizing a compound having one of...
|
|
WO/2010/144059A2 |
The present invention relates to the use of a compound represented by the general formula (I), and pharmaceutically acceptable salts thereof, wherein : n is an integer from 2 to 5; p is an integer from 0 to 4; R1 is selected from the gro...
|
|
WO/2010/139090A1 |
N-Phenyl dichloroacetamide and their derivatives which belong to pharmaceutical chemistry and organic synthesis fields are provided. These compounds have the structures of general formula I, in which N-{3-chloro-4-[(trifluoromethyl)sulfo...
|
|
WO/2010/136474A2 |
The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invent...
|
|
WO/2010/136221A1 |
The present invention relates to a novel class of compounds, namely dodeca-2E, 4E-diem amides and their use a medicament, preferably as a dermatologic agent, and as a cosmetic:. These novel compounds are particularly useful in treating a...
|
|
WO/2010/136493A1 |
The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the inv...
|
|
WO/2010/134014A1 |
The present invention relates to bridged spiro[2.4]heptane derivatives of formula (I), wherein W, Y, Z, R1 and R2 are as defined in the description, their preparation and their use as pharmaceutically active compounds as ALX receptor and...
|
|
WO/2010/132404A1 |
A new class of haloalkyl heteroaryl benzamides is described. These compounds show strong activity against hepatitis viruses.
|
|
WO/2010/128038A1 |
Compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meanings given in the specification, are useful in the treatment of neurodegenerative disease.
|
|
WO/2010/126086A1 |
Disclosed is a technique for efficiently producing a large amount of an amide compound at low cost, using an α,β-unsaturated carboxylic acid as a starting material, said amide compound being suitable for solvents and cleaning agents.
|
|
WO/2010/123832A2 |
The disclosure provides a series of 2-oxoamides based on dipeptides and pseudodipeptides, which were synthesized and their activities toward two human intracellular phospholipases A2 (GIVA CPLA2 and GVIA 1PLA2) and one human secretory ph...
|
|
WO/2010/122239A1 |
The invention relates to compounds of the formula (I) having a physiological effect, and to the preparation thereof and to the use of the same.
|
|
WO/2010/124152A1 |
Embodiments of the present invention disclose an agricultural composition that is a registerable, stable agricultural formulation that includes at least one nitrogen containing isethionic acid salt, at least one plant protection product,...
|
|
WO/2010/119222A1 |
The inventions relates to the compounds of formula (I) where: R is a hydrogen atom or a group selected from the (C1d- C6)alkyl and (C3-C7)-cycloalkyl groups, optionally substituted by one or more groups independently selected from a fluo...
|
|
WO/2010/119064A1 |
A process for the preparation of the compound of Formula (II): which process comprises reacting a compound of Formula (Vl): with a compound of Formula (IV): in a suitable solvent.
|
|
WO/2010/117598A2 |
A composition is disclosed comprising a hydrophobic monomer having the structure:CH2=CR4C(O)NHC(R1R1)(C(R1R1))nC(O)XR3 wherein n is an integer of 0 or 1; R1 is independently selected from at least one of: a hydrogen atom, alkyls, aryls, ...
|
|
WO/2010/116116A1 |
The present invention relates to a process for preparing a compound of formula wherein: R2 is cycloalkyl or alkyl, each of which may be optionally substituted; Y is -CONR3R4, -CN or CO2R5; R3, R4 and R5 are each independently H or alkyl;...
|
|
WO/2010/115666A1 |
The invention relates to a method for continuously producing alkylamino(meth)acrylamides by reacting alkyl(meth)acrylates with high-boiling amines. A catalyst activation and special regeneration technique allow for product qualities that...
|
|
WO/2010/113022A1 |
Provided are a novel compound which exhibits a plasminogen activator inhibitor-1 (PAI-1) inhibiting activity, a PAI-1 inhibitor which comprises said compound as an active component; and a pharmaceutical composition which comprises the co...
|
|
WO/2010/111849A1 |
A solid basic catalyst for synthesizing alkanolamide compounds has the following general formula [Mg1-xAlx(OH-)2]x+(OH-)x·mH2O, wherein 0.2≤x≤0.33 and 0.1
|
|
WO/2010/109301A1 |
The present invention relates to benzamidic compounds having general formula (I): wherein: Rx represents a halogen atom or a methyl group possibly substituted by fluorine atoms; R1, R2, R3, independently from each other, represent a C1- ...
|
|
WO/2010/108108A2 |
Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.
|
|
WO/2010/107487A2 |
New prodrugs are derived from highly water soluble parent drugs that exist as primary or secondary amines in their parent form. Lipophilic carrier groups are bonded to the parent drug via an amide linkage with additional linker elements ...
|
|
WO/2010/106215A1 |
Aminocyclitol compounds, procedure for the obtainment and uses thereof. Aminocyclitol compounds and uses thereof as pharmaceutical compositions for the treatment of diseases associated with alterations in iNKT cells, more specifically au...
|
|
WO/2010/108164A2 |
A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.
|
|
WO/2010/102554A1 |
A new crystalline form of Agomelatine, its preparation method and application are provided. There are main peaks where diffraction angles 2θ are 11.13, 11.82, 17.49, 18.29, 19.48, 19.72, 20.50, 21.76, 22.54, 22.97, 24.56, 25.36, 27.16 a...
|
|
WO/2010/103297A2 |
There is provided compounds of formula (I), wherein Y, ring A1 D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of dise...
|
|
WO/2010/103279A1 |
There is provided compounds of formula I, wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of ...
|
|
WO/2010/103273A2 |
The invention provides compounds which include L-DOPA or dopamine linked to an essential fatty acids. The general formula is set out below: R1-Z-O-(CH2)n-CH(R3)-(CH2)mO-Y-R2. R1 is derived from a fatty acid and R2 is from L-DOPA or dopam...
|
|
WO/2010/097052A1 |
Agomelatine hydrohalide complex and preparation method thereof are disclosed. Compared with agomelatine, agomelatine hydrohalide complex obtained by the present method has improved solubility, and is suitable for application need of prep...
|
|
WO/2010/097371A1 |
This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as w...
|
|
WO/2010/098496A1 |
A compound represented by the formula (I): wherein A and B each represent an aryl group or a heteroaryl group which may have a substituent, or a salt thereof can be produced by heating a compound represented by the formula (II): wherein ...
|
|
WO/2010/098023A1 |
Disclosed is a polymerizable monomer represented by formula (1) which is substituted by at least one group containing a polymerizable functional group. [In the formula, Ar1 and Ar4 to Ar6 independently represent a substituted or unsubsti...
|
|
WO/2010/094659A1 |
The invention relates to the use of compounds of formula (I), wherein the substituents are described in the description and claims, for the preparation of medicaments for the treatment of psychoses, dysfunction in memory and learning, sc...
|
|
WO/2010/094992A1 |
The invention pertains to the field of life necessities and more particularly relates to the cosmetic and/or dermatological fields, in particular the field of weight loss. The invention more particularly relates to esters or amides of co...
|
|
WO/2010/094679A1 |
Compounds of the formula (I) A is OH or a carbonyl group, n is 0 or 1, R is an alkyl radical having from 1 to 4 carbon atoms, in particular methyl, ethyl, n-propyl, iso -propyl, n-butyl or t-butyl; or a residue of a hydroxy carboxylic ac...
|
|
WO/2010/094289A1 |
The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.
|
|
WO/2010/094029A2 |
Cobalt(ll) complexes of the D 2-symmetric chiral porphyrins are effective catalysts for asymmetric cyclopropanation reactions with succinimidyl diazoacetate. The Co-catalyzed reaction is suitable for various olefins, providing the corres...
|
|
WO/2010/092180A1 |
The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of s...
|
|
WO/2010/093706A2 |
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
|
|
WO/2010/089984A1 |
Provided is a recording material which is excellent in the storage stability of the blank surface and an image, particularly, which is extremely excellent both in the light-resistance of the blank surface and in the light-, moisture- and...
|
|
WO/2010/091164A1 |
The present invention comprises glucosylceramide synthase (GCS) modulators of following structural formula (I); wherein R1, A, L, R2, R3, and m are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof...
|
|
WO/2010/088450A2 |
Provided herein are compounds, compositions, and methods for treating or ameliorating diseases associated with the modulation of SERCA.
|
|
WO/2010/086429A2 |
(S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid or (S)-pregabalin is an anticonvulsive drug. In addition to its use as an anticonvulsive agent, pregabalin has also been indicated as a medicament in the treatment of anxiety, neuropathic pa...
|
|
WO/2010/086366A1 |
The invention relates to compound of the formula (I) in which the substituents are as defined in the specification; m free form or in salt form; to its preparation, to its use as medicament and to medicaments comprising it.
|
|
WO/2010/086394A1 |
The present invention relates to a method for synthesizing a pharmaceutically acceptable acid addition salt of (1S, 2R)-milnacipran comprising the following successive steps: (a) reaction of phenylacetonitrile and of (R)-epichlorhydrin i...
|
|
WO/2010/084182A1 |
The present invention is directed to compounds, intermediates and methods for making valerenic acid and its derivatives as well as the use of such compounds as GABAA receptor ligands.
|
